NRAS and melanoma: Curtin and colleagues postulate that since N-RAS activates both the PI3K and MAPK pathway, while BRAF only activates the latter, it may suggest that in melanoma pathogenesis, somatic mutations activating one pathway require another event to activate other pathways [10].